Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients

OBJECTIVES: In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. N...

Descripción completa

Detalles Bibliográficos
Autores principales: Sejbaek, Tobias, Nielsen, Helle Hvilsted, Penner, Natasha, Plavina, Tatiana, Mendoza, Jason P, Martin, Nellie Anne, Elkjaer, Maria Louise, Ravnborg, Mads Henrik, Illes, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902070/
https://www.ncbi.nlm.nih.gov/pubmed/31611264
http://dx.doi.org/10.1136/jnnp-2019-321321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902070/
https://www.ncbi.nlm.nih.gov/pubmed/31611264
http://dx.doi.org/10.1136/jnnp-2019-321321

Ejemplares similares